0QYQ.LSE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

Loading chart

Pay with

0Q

Mkt Cap

N/A

Volume

N/A

Next Earnings

N/A

Chart Earnings News About Dividends Insider Filings

Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBCGilead Sciences recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, highlighting significant benefits in treating metastatic triple-negative breast cancer. This development may have supported the company's 12% price gain in the last quarter, compleme…finance.yahoo.com · Apr 21, 2025

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC – – Trodelvy Plus Keytruda Shows an Early Trend in Improvement for Overall Survival Versus Stan…finance.yahoo.com · Apr 21, 2025

Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars ProgramNORTHAMPTON, MA / ACCESS Newswire / April 15, 2025 / As a medical oncologist who has practiced in three different countries, Dr. Maria Alice Franzoi is well acquainted with various healthcare systems and has a keen interest in researching patient-centered care models and innovati…finance.yahoo.com · Apr 15, 2025

How to Play the Biotech Meltdown in the Age of RFK Jr. and TariffsPolitical pressure and persistently high interest rates have some wondering if the industry’s model is broken. Continue Reading View Commentsfinance.yahoo.com · Apr 11, 2025

Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025FOSTER CITY, Calif., April 10, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s…finance.yahoo.com · Apr 10, 2025

PatientView Ranks Gilead "Best" at ESGNORTHAMPTON, MA / ACCESS Newswire / April 10, 2025 / At Gilead, putting people first is central to all we do. That's why we're proud to be recognized as a responsible company by patient advocacy groups representing more than 70 countries. In a new report from UK-based PatientView…finance.yahoo.com · Apr 10, 2025

Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B CoinfectionsNORTHAMPTON, MA / ACCESS Newswire / April 8, 2025 / In 2019, Somchai, a Thai native, was 21 years old and faced a double threat to his long-term health and wellbeing. He was living with hepatitis B (HBV) and with advanced HIV. "Since both viruses are bloodborne and transmitted in…finance.yahoo.com · Apr 8, 2025

Biotech stocks slide as Marks resignation seen being negative for sectorShares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry…finance.yahoo.com · Apr 1, 2025

Discovering a Breakthrough: Gilead’s Long-Standing Commitment to Helping Change the Course of HIVNORTHAMPTON, MA / ACCESS Newswire / April 1, 2025 / In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited. He was 12 years into his virology research ca…finance.yahoo.com · Apr 1, 2025

These biotech names aren't facing 'huge concern' from tariffsTrump's upcoming tariffs has the potential to bring biopharma manufacturing to the US, which could impact companies with overseas production. Jefferies managing director Michael Yee joins Market Domination Overtime to discuss how tariffs could impact the biotech sector, emphasizi…finance.yahoo.com · Apr 1, 2025

to start trading

0Q

0QYQ.LSE0QYQ.LSE

0QYQ.LSE

Pay with—

Available Balance0.00

Your PositionYou don't own any 0QYQ.LSE yet.

Related Tickers

Earnings

Dividends

Last · Sep 14Quarterly

Amount$0.82

Yield207.67%

Annual$3.25